https://www.selleckchem.com/pr....oducts/as1517499.htm
There are few data regarding multiple switching from the originator Infliximab to its biosimilars. To assess outcomes and patient perspectives in a prospective manner after double switching from Infliximab to the biosimilars CT-P13 and SB2. A total of 158 consecutive patients with inflammatory bowel disease (IBD) receiving CT-P13 maintenance therapy were switched to SB2 and followed for 54weeks. Patients were stratified according to previous switch from the originator Infliximab to CT-P13 (double switch group) or not (single switch gr
Like
Comment
Share
